Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Shareholder Meeting (May 2022)
17 slides from Elixinol Wellness's shareholder meeting presentation, May 26, 2022
Slide 1: Annual General Meeting 26 May 2022
For personal use only ASX:EXL Annual General Meeting 26 May 2022 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation contains summary information about Elixinol Wellness Limited (Elixinol Wellness) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with Elixinol Wellness
Slide 3: Agenda
Agenda For personal use only Introduction Chair's address CEO update Official business Q&A 33
Slide 4: Introduction
For personal use only Introduction 4
Slide 5: Chair’s Address
For personal use only Chair’s Address 5
Slide 6: CEO Update
For personal use only CEO Update 6
Slide 7: Vision, Ambition and Purpose
Elixinol CBD Brand (Digestible & Topical Products) VISION To create a healthier everyday For personal use only life through the power of hemp and plant-based products AMBITION Building a global, hemp-centric wellness consumer products company PURPOSE Hemp Foods Australia (Foods, Supplements & Skinca
Slide 8: Year in Review
Year in Review For personal use only March 2021 March 2021 May 2021 May 2021 June 2021 July 2021 Elixinol Global announces Elixinol, under its European Elixinol Wellness Elixinol Global Limited Elixinol Wellness Hemp Foods Australia’s it has signed a binding Industrial Hemp Association appoints Rob
Slide 9: FY21 Financial Highlights
FY21 Financial Highlights Elixinol Wellness is on a consistent EBITDA improvement trajectory having delivered its best EBITDA For personal use only performance in recent periods and continues well capitalized with a strong cash position. FY21 Revenues: $9.3m (-38% vs PY) A$’000, FY21 1,011 988 914 8
Slide 10: FY21 Operational Highlights
FY21 Operational Large scale business transformation drives $11.3m Investment focus on AU and US markets with strongest competitive position simplifies Highlights OPEX savings with further For personal use only our business model and enables optimisation initiatives available. group to compete more
Slide 11: Q1 FY22 Key Highlights
Q1 FY22 Key Highlights Despite seasonal and omicron softness impacting revenues in Q1 FY22, we have maintained For personal use only our trajectory to drive EBITDA improvement. Solid funding position FSA approval of Elixinol’s UK product range US digital revenue Cash reserves of $10.8m* and reduced
Slide 12: Digital Growth Strategy Driving Growth and Profitability
Digital Growth Strategy Driving Growth and Profitability For personal use only 39% of revenue was derived from e-commerce in FY21 (FY20: 33%). Continued efforts to move toward a digital growth business have yielded strong progress, with more upside ahead as the business focused on attracting new con
Slide 13: Outlook: Hemp food and CBD products and plant-based nutrition
Outlook: Hemp food and CBD products an answer to the growing trend for plant-based nutrition and nutraceuticals For personal use only Hemp food in Australia CBD in U.S.A. The rise in dietary trends such as vegan / vegetarian and flexitarian has seen Sales are expected to reach $12.0 billion by 2026,
Slide 14: Global Strategy & Initiatives
Global Strategy & Initiatives VISION: To create a healthier everyday life through the power of hemp & plant-based products For personal use only REGIONAL PRIORITIES: As we re-build profitability, we will focus our investments on our most established markets in the US and Australia where we have a st
Slide 15: New Product Development Initiatives
New Product Development Initiatives FY21 investment in building a R&D and innovation capability has delivered a wide reaching new product launch pipeline that will see new For personal use only product throughout H1 FY22. LAUNCHED COMING • Sleep Liposomes • Functional gummies Elixinol will expand CB
Slide 16: Summary
Well positioned in global consumer wellness trend For personal use only for natural and plant-based food and nutraceuticals Business transformation Improved outlook to a leaner cost structure, further due to a better economic strengthening fundamentals environment and end of COVID- 19 restrictions S
Slide 17: Thank you
For personal use only Thank you 17